Evidence map›Paper›PMID 37018235›Full record

ArticlePLoS neglected tropical diseases2023

Acceptability of test and treat with doxycycline against Onchocerciasis in an area of persistent transmission in Massangam Health District, Cameroon.

Rogers Nditanchou, Ruth Dixon, Kareen Atekem, Serge Akongo, Benjamin Biholong, Franklin Ayisi, Philippe Nwane, Aude Wilhelm, Sapana Basnet, Richard Selby and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Rogers NditanchouSightsavers, Cameroon Country Office, Cameroon.ORCID 0000-0001-7472-4608
Ruth DixonSightsavers, Haywards Heath, United Kingdom.
Kareen AtekemSightsavers, Cameroon Country Office, Cameroon.
Serge AkongoSightsavers, Cameroon Country Office, Cameroon.
Benjamin BiholongNational Programme for the Fight against Onchocerciasis and Lymphatic Filariasis, Ministry of Public Health, Yaoundé, Cameroon.
Franklin AyisiNational Programme for the Fight against Onchocerciasis and Lymphatic Filariasis, Ministry of Public Health, Yaoundé, Cameroon.
Philippe NwaneFilariasis and other Tropical Neglected Diseases Research Center, Yaoundé, Cameroon.
Aude WilhelmSightsavers, Haywards Heath, United Kingdom.
Sapana BasnetSightsavers, Haywards Heath, United Kingdom.
Richard SelbySightsavers, Haywards Heath, United Kingdom.
Samuel WanjiResearch Foundation in Tropical Diseases and Environment, Buea, Cameroon.
Didier BakajikaWHO/Regional Office for Africa, Brazzaville, Republic of the Congo.
Joseph OyeSightsavers, Cameroon Country Office, Cameroon.
Joseph KamgnoFilariasis and other Tropical Neglected Diseases Research Center, Yaoundé, Cameroon.
Daniel BoakyeParasitology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Elena SchmidtSightsavers, Haywards Heath, United Kingdom.
Laura SenyonjoSightsavers, Haywards Heath, United Kingdom.
Sightsavers · GBMinistry of Public Health · CMUniversité de Yaoundé I · CMUniversity of Buea · CMUniversity of Ghana · GHWorld Health Organization Regional Office for Africa · CG

Funding

World Health Organization 001
6 · The paper itself

Abstract

The main onchocerciasis elimination strategy is annual Community-Directed Treatment with ivermectin (CDTi). However, as a response to persistent high infection prevalence in Massangam Health District in Cameroon, two rounds of alternative treatments including biannual CDTi, ground larviciding and test and treat with doxycycline (TTd) were implemented. This led to a significant prevalence reduction from 35.7% to 12.3% (p<0.001) as reported by Atekem and colleagues. Here we report on the acceptability of TTd component based on qualitative and quantitative data. The TTd involved microscopic examination for microfilaria in skin biopsy and those infected were offered doxycycline 100 mg daily for 35 days by community-directed distributors (CDDs). Participation level was significantly high with 54% of eligible population (age > 8, not pregnant, not breastfeeding, not severely ill,) participating in the test in each round, increasing to 83% over the two rounds. Factors associated with non-participation included mistrust, being female; being younger than 26 years; short stay in the community; and belonging to semi-nomadic sub population due to their remote and disperse settlement, discrimination, their non selection as CDD, and language and cultural barriers. Treatment coverage was high -71% in round 1 and 83% in round 2. People moving away between testing and treatment impacted treatment coverage. Some participants noted mismatch between symptoms and test result; and that ivermectin is better than doxycycline, while others favoured doxycycline. CDD worried about work burden with unmatching compensation. Overall, TTd participation was satisfactory. But can be improved through reinforcing sensitisation, reducing time between test and treatment; combining TTd and CDTi in one outing; augmenting CDDs compensation and/or weekly visit; exploring for frequently excluded populations and adapting strategies to reach them; and use of a sensitive less invasive test.

Indexed as

OnchocerciasisCameroonDoxycyclineFemaleHumansIvermectinMalePregnancyPrevalenceDoxycyclineIvermectin

Identifiers

PMID37018235
PMCPMC10075443
OpenAlexW4362601099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.